Synartro

Russia
Kholbon, Zabaykalskiy (Transbaikal) Kray, Russia, 754 37

Company profile

Synartro company profile

Synartro is a Swedish research and development company that develops improved treatments using patented delivery technology combined with existing proven drugs. The preclinical lead program, SYN321, is based on a novel therapy combining diclofenac covalently bound to hyaluronan for the treatment of osteoarthritis (OA), a disease that today leaves up to 50% of patients without adequate pain relief. The company’s initial focus is in knee OA with the potential of further expansion.

Business identity

Operating status
Active
Company type
For Profit
Employee range
1-10 employees
Revenue range
$0-$1M
Founded
2011-01-01

Headquarters

Postal code
754 37
Country code
RU
Continent
Europe

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
3
Total equity funding
$6.6M
Last funding
Series A / $3.9M / 2021-09-30
Last equity funding
Series A / $3.9M
Investors
1
Lead investors
1
Founders
1
Articles
9

Founders and investors

Founders

Fredrik Lehmann

Lead investors

Sciety

Investors

Sciety